Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with or without GEMOX in Advanced HCC
NCT00941967Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Dec 2008
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and oxaliplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoints: Progression-free survival at 18 months and Tumor response according to RECIST criteria at 18 months. Started Dec 2008; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00941967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941967.